Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts’ Opinion using a Delphi Approach-Reference-Cited by-同舟云学术

Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts’ Opinion using a Delphi Approach

Published:2023-11 Issue:11 Volume:21 Page:2206-2216
ISSN:1570-159X
Container-title:Current Neuropharmacology
language:en
Short-container-title:CN

Author:

Dell’Osso Bernardo¹²³,Bellomo Antonello⁴,Maria Conca Andreas Pietro⁵⁶,Salvi Virginio⁷,Siracusano Alberto⁸,Zaffora Carmelo⁹,De Berardis Domenico¹⁰,Di Giannantonio Massimo¹¹

Affiliation:

1. Department of Mental Health and Addiction, University of Milan, ASST Fatebenefratelli-Sacco, Milan, Italy

2. "Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Milan, Milan, Italy

3. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA

4. Department of Clinical and Experimental Medicine, Psychiatric Unit, University of Foggia, Foggia, Italy

5. NHS, National Health Service, Department of Mental Health, Bolzano, Italy

6. Auxiliary University Department, Medical University of Innsbruck and Paracelsus Medizinische Privatuniversität (PMU), Salzburg, Austria

7. Department of Clinical Neurosciences/DIMSC, Università Politecnica delle Marche, Ancona, Italy

8. Psychiatric Clinic, PTV Foundation - Policlinico Tor Vergata University of Rome, Rome, Italy

9. NHS, National Health Service, Department of Mental Health, Azienda Sanitaria Provinciale (ASP 3), Catania, Italy

10. NHS, National Health Service, Department of Mental Health, ASL 4, Teramo, Italy

11. Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Pescara, Chieti, Italy

Abstract

Background: Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient’s quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability. Objective: To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique. Method: A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%). Results: Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data. Conclusions: These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology,General Medicine